Table 1. Characteristics of studies included in meta-analysis.
| Author | year | country | Sample number | Average age (years) | Use method of loading dose group | Use method of conventional dose group | outcome Measures | ||
|---|---|---|---|---|---|---|---|---|---|
| R | C | R | C | ||||||
| Wu HB[22] | 2013 | china | 50 | 50 | 59.28±9.02 | 56.28±9.81 | Oral(20 mg/day) | Oral(10 mg/day) | hs-CRP, TG, TC, LDL-C |
| Xu CZ[23] | 2013 | china | 45 | 45 | 53~84 | 53~84 | Oral(20 mg/day) | Oral(10 mg/day) | hs-CRP, TG, TC, LDL-C, HDL-C |
| Zou Y[24] | 2012 | china | 43 | 37 | 56±10.1 | 56±10.6 | Oral(20 mg/day) | Oral(10 mg/day) | hs-CRP, TG, TC, LDL-C, HDL-C |
| Chen QY[25] | 2016 | china | 30 | 31 | 20~75 | 20~75 | Oral(20 mg/day) | Oral(10 mg/day) | hs-CRP, TG, TC, LDL-C |
| Jiao YG[26] | 2014 | china | 33 | 39 | 59.3±11.8 | 60.9±10.7 | Oral(20 mg/day) | Oral(10 mg/day) | hs-CRP, TC, LDL-C,TnT |
| Li H[27] | 2014 | china | 30 | 30 | 65.2±2.4 | 66.3±2.6 | Oral(20 mg/day) | Oral(10 mg/day) | hs-CRP |
| Gui W[28] | 2014 | china | 26 | 26 | 54.2±7.8 | 53.2±6.8 | Oral(20 mg/day) | Oral(10 mg/day) | hs-CRP, TG, TC, LDL-C, HDL-C |
| Yang Y[29] | 2015 | china | 20 | 20 | 59±8.65 | 59±8.65 | Oral(20 mg/day) | Oral(10 mg/day) | TnT |
| Shi YB[30] | 2013 | china | 20 | 20 | 69.10±11.95 | 70.90 ±13.72 | Oral(20 mg/day) | Oral(10 mg/day) | TG, TC, LDL-C |
| Liao BH[31] | 2013 | china | 70 | 70 | 58.91±12.52 | 61.38±14.33 | Oral(20 mg/day) | Oral(10 mg/day) | hs-CRP |
| Luo J[32] | 2012 | china | 31 | 36 | 58.3±11.8 | 60.6±8.8 | Oral(20 mg/day) | Oral(10 mg/day) | TnT |
Loading dose of Rosuvastatin group = R; Conventional dose Rosuvastatin group = C; hypersensitive C reactive protein = hs-CRP; triglyceride = TG; total cholesterol = TC; Low-density lipoprotein = LDL-C; High Density Lipoprotein = HDL-C; Cardiac troponin T = TnT